Profile photo Tolboom

Tolboom

Assistant Professor - medical

Strategic program(s):

Biography

Nuclear medicine physician,
Department of Radiology and Nuclear Medicine, University Medical Centre Utrecht and Princess Maxima Centre for pediatric oncology, Utrecht (fixed term).

Specific clinical fields of interest:
Nuclear Neuro-imaging (i.e. neuro-oncology, epilepsy, neurodegeneration), Pediatric nuclear imaging, Hemato-oncology, Head and Neck oncology, Nuclear therapies (theranostics)

Research line: 
Clinical neuro imaging (co-PI of multicenter study using FET PET for management of glioblastoma, local PI of multicenter TAU PET study investigating clinical value of TAU PET in neurodegeneration), national PI for an European Organization for Research and Treatment of Cancer (EORTC) initiated nuclear treatment study in Meningioma (‘LUMEN’ study). Experimental neuroimaging using neuroinflammation tracers (PI of multi-center study using neuroinflammation PET).

Leadership:
-Member and vice chair of EORTC Brain tumour group/ nuclear medicine committee.
-Member of Neuroimaging committee, European Association of Nuclear Medicine (EANM)
-EANM representative for the European Academy of Neurology (EAN), member of management group of EAN scientific panel on neuroimaging.
-EANM liaison person to the EAN Brain Health Summit initiative.
-Co-Chair of Dutch Society for Nuclear Medicine Neuroimaging committee.

Research groups

Nuclear theranostics research

Research aim

With nuclear theranostics we aim to develop radiopharmaceuticals to improve the disease diagnosis and therapy, including clinical translation for direct impact. Disease areas of interest are (childhood) cancer, neurology and infectious diseases.

Go to group

Clinical and translational neuro-oncology

Research aim

We aim to improve treatments and clinical outcomes of patients with gliomas and other brain tumors, by combining expertise from oncobiology, neuropsychology, imaging, surgical & clinical neurology, and palliative care.

Go to group

Recent publications

Patient perspectives on diagnostic uncertainty and novel diagnostic tests in neuro-oncology Veerle J. Ruijters, Marloes M. Bauer, Nelleke Tolboom, Tatjana Seute, Leonie N.C. Visser, Tom J. Snijders
Neuro-Oncology Practice, 2026, vol. 13, p.733-742
Interictal PET and Its Value in the Localization of the Seizure-Onset Zone Nelleke Tolboom, Alfred Meurs, Donatienne Van Weehaeghe
2026, p.81-87
Drawing parallels between amyloid PET in Alzheimer’s disease and amino acid PET in primary and secondary brain tumors Nelleke Tolboom, Antoine Verger, Matthias Preusser, Marjolein Geurts, Philip Scheltens, Nathalie Lisa Albert
Neuro-oncology advances, 2026, vol. 8
Near complete response recurrent glioblastoma after treatment with [131I]-Iodofalan A. El Ghalbouni, T. J. Snijders, N. Tolboom, A. J.A.T. Braat
European Journal of Nuclear Medicine and Molecular Imaging, 2026, vol. 53, p.4785-4787
Efficacy of Intra-arterial [177Lu]Lu-DOTATATE monotherapy for treatment-refractory meningioma A. El Ghalbouni, T. J. Snijders, A. Amerein, N. Tolboom, M. Patt, C. J. Maurer, I. C. van der Schaaf, C. Lapa, A. J.A.T. Braat
Journal of Neuro-Oncology, 2026, vol. 176, p.1-9
Case 49 Nelleke Tolboom, Tom J. Snijders, Irene C. Van der Schaaf, Arthur J.A.T. Braat
2025, p.241-245